Press Releases

 
Press Releases
Date Title and Summary View
Oct 17, 2014 SALT LAKE CITY, Oct. 17, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for Prolaris, Myriad's revolutionary prostate cancer test. The LCD is posted to...
Oct 8, 2014 SALT LAKE CITY, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of R. Bryan Riggsbee as executive vice president, Chief Financial Officer, and Treasurer effective October 16, 2014. Jim Evans will continue in his role as Chief Financial Officer through the transition to Mr. Riggsbee. "I am del...
Sep 29, 2014 SALT LAKE CITY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Tumor BRACAnalysis CDx™ companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Soc...
Sep 9, 2014 SALT LAKE CITY, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical utility study of the Myriad myPath™ Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a novel diagnostic test that differentiates maligna...
Sep 3, 2014 SALT LAKE CITY, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that the Myriad myRisk™ Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer (http://onlinelibrary.wiley.com/doi/1...
Aug 28, 2014 SALT LAKE CITY, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:45 a.m. Eastern time on September 10, 2014, at the Grand Hyatt in New York City. The presentation will be avai...
Aug 12, 2014 SALT LAKE CITY, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2014, provided an update on recent business highlights, and provided financial guidance for its fiscal year ending June 30, 2015. Revenue for the fiscal fourth quarter w...
Jul 30, 2014 SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014. The Company also will host a conference ...
Jun 10, 2014 Vectra®DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European League Against Rheum...
Jun 9, 2014 SALT LAKE CITY, June 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until a replacement can be foun...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase